Home
Statistics
Acknowledgment
Enquire
Keyword Search
Complex Search
Segment Search
Peptide Mapping
Browse On
Mode of delivery
Animal model
Origin/Source
Peptide Length
Similarity
BLAST Search
Smith-Waterman
General
Help or Guide
Data Submission
Curators
Developers
Contact Us
Browse result page of B3Pdb
The total number entries retrieved from this search are
76
, scroll left/right for detailed information.
B3pdbID
PEPTIDE NAME
PEPTIDE SEQUENCE (1-letter)
PEPTIDE SEQUENCE (3-letter)
N-TERMINAL MODIFICATION
C-TERMINAL MODIFICATION
CHEMICAL MODIFICATION
PEPTIDE LENGTH
PEPTIDE CONFORMATION
PEPTIDE NATURE
SOURCE/ORIGIN OF PEPTIDE
SMILES
CELL LINE
In vitro
CONCENTRATION
In vitro
METHOD
In vitro
RESULT
ANIMAL MODEL
In vivo
CONCENTRATION
In vivo
MODE OF DELIVERY
In vivo
METHOD
In vivo
RESULT
ACTION
TRANSPORT TYPE
SUBCELLULAR LOCALISATION
COMBINATION
PHYSICAL CONDITION
RESPONSE
RESULT
LABEL
PMID
b3pdb_0008
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.3 micromolar
NA
30824786
b3pdb_0009
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
1.6 ± 0.9micromolar
NA
30824786
b3pdb_0010
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
1.6 ± 0.8 micromolar
NA
30824786
b3pdb_0011
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Alone
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0012
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0013
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA N315
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Alone
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0014
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0015
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.9 micromolar
NA
30824786
b3pdb_0016
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.7 micromolar
NA
30824786
b3pdb_0017
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.4 micromolar
NA
30824786
b3pdb_0018
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.3 micromolar
NA
30824786
b3pdb_0019
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA 12673
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
0.8 ± 0.3 micromolar
NA
30824786
b3pdb_0020
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows high sensitivity
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0021
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.3 micromolar
NA
30824786
b3pdb_0022
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0023
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
1.6 ± 0.4 micromolar
NA
30824786
b3pdb_0024
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0025
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
S. aureus MRSA hetero-VISA 6347b
100000 CFU/mL
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
3.1 ± 0.8 micromolar
NA
30824786
b3pdb_0026
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.4 micromolar
NA
30824786
b3pdb_0027
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
50.0 ± 10.2 micromolar
NA
30824786
b3pdb_0028
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 5.1 micromolar
NA
30824786
b3pdb_0029
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 3.2 micromolar
NA
30824786
b3pdb_0030
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.7 micromolar
NA
30824786
b3pdb_0031
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecium 3934825
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.7 micromolar
NA
30824786
b3pdb_0032
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
12.5 ± 2.2 micromolar
NA
30824786
b3pdb_0033
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows intermediate susceptibility.
NA
NA
Combined with Vanomycin
NA
MIC
6.3 ± 1.6 micromolar
NA
30824786
b3pdb_0034
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
N-terminal Fmoc group was removed and the propiola
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.5 micromolar
NA
30824786
b3pdb_0035
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 5.1 micromolar
NA
30824786
b3pdb_0036
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
NA
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.9 micromolar
NA
30824786
b3pdb_0037
Transportan 10
AGYLLGKINLKALAALAKKIL
AlaGlyTyrLeuLeuGlyLysIleAsnLeuLysAlaLeuAlaAlaLeuAlaLysLysIleLeu
6-carboxyfluorescein (Fl) was coupled to the N-ter
Amide group is attached
NA
21
Linear
Cationic
Chemically synthesized
N[C@@]([H])(C)C(=O)NCC(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)O
Enterococcus faecalis 3937158
NA
NA
NA
BALB/c mice
60 mg/kg
Intravenous
Fluorescence microscopy assay
It crosses the BBB.
It shows the resistance
NA
NA
Combined with Vanomycin
NA
MIC
25.0 ± 6.9 micromolar
NA
30824786
b3pdb_0042
MVIIA (ziconotide)
CKGKGAKCSRLMYDCCTGSCRSGKC
CysLysGlyLysGlyAlaLysCysSerArgLeuMetTyrAspCysCysThrGlySerCysArgSerGlyLysCys
NA
TAT-transducing domain was fused at C-terminal
NA
25
Linear
Cationic
NA
N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)NCC(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(CCSC)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)O)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)NCC(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])(CS)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CO)C(=O)NCC(=O)N[C@@]([H])(CCCCN)C(=O)N[C@@]([H])(CS)C(=O)O
HEK293 cells
NA
Acetic Acid-Induced WRITHING test
Inhibitory activity toward N-type calcium channels.
Kunming mice
NA
Intranasal and Intervenous
Tremor Symptom Test
It induces tremor symptoms
It showed that C-terminal fusion with TAT peptide render its BBB penetration capacity, without signi
Receptor-mediated transcytosis
NA
Comined with TAT-protein
NA
MIC
0.0436 micromolar
NA
31083641
b3pdb_0049
gH625Cys
HGLASTLTRWAHYNALIRAF
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPhe
Acetylaed at N-terminal
Cys-CONH2 group is attached at C-terminal
NA
21
Linear
NA
Chemically synthesized
N[C@@]([H])(CC1=CN=C-N1)C(=O)NCC(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CO)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(O)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(CC(=CN2)C1=C2C=CC=C1)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC1=CN=C-N1)C(=O)N[C@@]([H])(Cc1ccc(O)cc1)C(=O)N[C@@]([H])(CC(=O)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(CC(C)C)C(=O)N[C@@]([H])([C@]([H])(CC)C)C(=O)N[C@@]([H])(CCCNC(=N)N)C(=O)N[C@@]([H])(C)C(=O)N[C@@]([H])(Cc1ccccc1)C(=O)O
BMECs
5 micromolar
Fluorescence microscopy
Liposomes preparations were non-toxic for the endothelial cells and improves the transfer of liposom
Mouse
NA
Intravenous
Fluorescence microscopy
gH625 ameliorates the efficiency of liposomes to deliver. PACAP
gH625-liposomes represent a promising strategy to deliver therapeutic agents to CNS and to provide a
NA
NA
Comined with liposome
NA
NA
NA
NA
31235716
b3pdb_0162
ASA-ApoEI
TEELRVRLASHLRKLRKRLLRDA
ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla
Conjugated with ASA drug
NA
NA
23
Linear
NA
NA
NA
CHO cell line
2.5 microgram/ ml
cellular uptake assay
93 % cellular uptake
NA
NA
NA
NA
NA
NA
Transendocytosis
NA
NA
Lysosomal disorder
NA
NA
NA
24573272
b3pdb_0167
ASA-ApoEI
TEELRVRLASHLRKLRKRLLRDA
ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla
Conjugated with ASA drug
NA
NA
23
Linear
NA
NA
NA
bEND cell line
2.5 microgram/ ml
cellular uptake assay
21.2 % cellular uptake
NA
NA
NA
NA
NA
NA
Transendocytosis
NA
NA
Lysosomal disorder
NA
NA
NA
24573272
b3pdb_0172
ASA-ApoEI
TEELRVRLASHLRKLRKRLLRDA
ThrGluGluLeuArgValArgLeuAlaSerHisLeuArgLysLeuArgLysArgLeuLeuArgAspAla
Conjugated with ASA drug
NA
NA
23
Linear
NA
NA
NA
PBCECs cell line
0.02% cells were added
Basolateral screening assay
200% transfer
NA
NA
NA
NA
NA
NA
Basolateral
NA
NA
Lysosomal disorder
NA
NA
NA
24573272
b3pdb_0193
gH625
HGLASTLTRWAHYNALIRAFGGG
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly
NA
NA
Chemically synthesized
23
Linear
NA
NA
NA
Human neuroblastoma cell line SH-SY5Y
5*10^4 cells/well
Spectorcluorometric analysis
20% fluoroscence measured at 1 micromolar peptide concentration
NA
NA
NA
NA
NA
NA
Transcytosis
NA
NA
NA
NA
NA
NA
25792823
b3pdb_0194
gH625
HGLASTLTRWAHYNALIRAFGGG
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly
NA
NA
Chemically synthesized
23
Linear
NA
NA
NA
Human glioblastoma cell line U-87
5*10^4 cells/well
Spectorcluorometric analysis
35% fluoroscence measured at 1 micromolar peptide concentration
NA
NA
NA
NA
NA
NA
Transcytosis
NA
NA
NA
NA
NA
NA
25792823
b3pdb_0195
gH625
HGLASTLTRWAHYNALIRAFGGG
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly
NA
NA
Chemically synthesized
23
Linear
NA
NA
NA
Human neuroblastoma cell line SH-SY5Y
5*10^4 cells/well
Spectorcluorometric analysis
80% fluoroscence measured at 1 micromolar peptide concentration
NA
NA
NA
NA
NA
NA
Transcytosis
NA
NA
NA
NA
NA
NA
25792823
b3pdb_0196
gH625
HGLASTLTRWAHYNALIRAFGGG
HisGlyLeuAlaSerThrLeuThrArgTrpAlaHisTyrAsnAlaLeuIleArgAlaPheGlyGlyGly
NA
NA
Chemically synthesized
23
Linear
NA
NA
NA
Human glioblastoma cell line U-87
5*10^4 cells/well
Spectorcluorometric analysis
90% fluoroscence measured at 1 micromolar peptide concentration
NA
NA
NA
NA
NA
NA
Transcytosis
NA
NA
NA
NA
NA
NA
25792823
b3pdb_0378
penetratin-scFv
NSRQIKIWFQNRRMKWKKGSS
AsnSerArgGlnIleLysIleTrpPheGlnAsnArgArgMetLysTrpLysLysGlySerSer
NA
NA
NA
21
Linear
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
23941991
b3pdb_0716
human Obestatin
FNAPFDVGIKLSGVQYQQHSQAL-NH2
Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH2
NA
NA
NA
23
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_0718
Endothelin-1
CSCSSLMDKECVYFCHLDIIW
Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp
NA
NA
Cys1-Cys15, Cys3-Cys11
21
Linear
NA
human
CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CNC2=CC=CC= C21)C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3=CNC= N3)NC(=O)[C@@H]4CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H]5CSSC[C@@H](C(=O)N[C@ H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4)CC6=CC=CC=C6)CC7=CC=C(C=C7)O)C(C)C)NC (=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@ @H](NC(=O)[C@@H](NC5=O)CO)CO)CC(C)C)CCSC)CC(=O)O)CCCCN)CCC(=O)O)CO)N
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
b3pdb_0775
mouse Obestatin
FNAPFDVGIKLSGAQYQQHGRAL-NH2
Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg- Ala-Leu-NH2
NA
NA
NA
23
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
non saturable
NA
NA
NA
Unidirectional influx rate constant
0.00186 mL/(g x min)
Direct iodination
16476508
b3pdb_0776
mouse Obestatin
FNAPFDVGIKLSGAQYQQHGRAL-NH2
Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg- Ala-Leu-NH2
NA
NA
NA
23
Linear
NA
Chemically synthesized
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
non saturable
NA
NA
NA
Initial disrobution volume
0.01853 ml/g
Direct iodination
16476508
b3pdb_0985
Transportan 10
AGYLLGKINLKALAALAKKIL-NH2
Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
NA
NA
NA
21
Linear
NA
synthetic,viral
NA
NA
NA
Efflux study ICU
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Brain elemination rate constant
0.0866 min-1
Direct iodination
26465925
b3pdb_0986
Transportan 10
AGYLLGKINLKALAALAKKIL-NH2
Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
NA
NA
NA
21
Linear
NA
synthetic,viral
NA
NA
NA
Capillary depletion
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
% capillary
14.96%
Direct iodination
26465925
b3pdb_0987
Transportan 10
AGYLLGKINLKALAALAKKIL-NH2
Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
NA
NA
NA
21
Linear
NA
synthetic,viral
NA
NA
NA
Capillary depletion
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
% parenchyma
85.04%
Direct iodination
26465925
b3pdb_0988
Transportan 10
AGYLLGKINLKALAALAKKIL-NH2
Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
NA
NA
NA
21
Linear
NA
synthetic,viral
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Unidirectional influx rate constant
0.00005 mL/(g x min)
Direct iodination
26465925
b3pdb_0989
Transportan 10
AGYLLGKINLKALAALAKKIL-NH2
Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Ala-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
NA
NA
NA
21
Linear
NA
synthetic,viral
NA
NA
NA
NA
NA
NA
NA
Intravenous
NA
NA
NA
Permeability
NA
NA
NA
Initial disrobution volume
0.00988 ml/g
Direct iodination
26465925
b3pdb_0990
TP10-2
AGYLLGKINLKPLAALAKKIL-NH2
Ala-Gly-Tyr-Leu-Leu-Gly-Lys-Ile-Asn-Leu-Lys-Pro-Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NH2
NA
NA
NA
21
Linear
NA
Chemically synthesized
NA
NA
NA
Efflux study ICU
NA
NA
NA
NA
NA
NA
NA
Permeability
NA
NA
NA
Brain elemination rate constant
0.0624 min-1
Direct iodination
26465925
previous
1
2
next
IIITD/CB
Raghava's Group
IMTECH
CellPPDMOD
